Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 152 full-time employees. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The firm's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
06996.HK stock price ended at $0 on 星期三, after dropping NaN%
On the latest trading day Jan 28, 2026, the stock price of 06996.HK fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for 06996.HK decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.